BlogPeptide guides › AOD-9604
Healing / Recovery · Research guide

AOD-9604 peptide: Healing / Recovery research guide

Catalogue reference · Laboratory research only

Not medical advice. AOD-9604 is sold for research. This guide does not recommend dosing, diagnosis, or therapy.

AOD-9604 is listed in our catalogue under “Healing / Recovery.” In scientific publications it is discussed in technical language; this page translates the general themes into everyday wording while staying faithful to research-only framing.

Plain-language snapshot

One-paragraph overview from our research datasheet—still scientific, but faster to read than the full mechanism list below.

AOD-9604 — tyrosine-modified C-terminal HGH fragment (177-191) with β3-adrenergic receptor-mediated lipolysis and GRAS safety designation.

What shows up in scientific writing (general background)

Many readers want context before diving into pathways. The list below summarises what researchers and reviewers discuss—cells, animals, and (for some drug-class molecules) formal clinical trials. It is not a promise of results for any individual.

“Reported” means described in the literature, not recommended for personal use. Our peptides are for laboratory research only.

Typical study contexts & reported directions

Why Healing / Recovery research discusses this compound

Compounds in this family are frequently studied in models of tissue injury, wound closure, and how cells reorganise after damage. Research looks at cell movement, blood-vessel support, and inflammatory balance -not at replacing medical care.

Themes from preclinical literature (technical)

Below are mechanistic bullet points as they appear in our product reference material -useful for researchers comparing pathways. They are not simplified health claims.

Typical handling notes (from our datasheet)

Storage: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. ~5% degradation per year refrigerated. - see our storage guide for best practices on temperature, light, and shelf life.

Typical research dosing discussion (literature-style): 250–500 mcg subcutaneously · Once daily, administered fasted · Serum t½ ≈ 3–4 min (rapid amino-terminal truncation cascade); primary metabolites (-2aa, -3aa) retain partial anti-lipogenic activity; ~40% oral bioavailability in pigs; clinical trial oral doses: 0.25–1 mg/day. Metabolic effects persist beyond peptide clearance. NOAEL: 100 mg/kg/day (rats), 50 mg/kg/day (cynomolgus monkeys).

For preparation, follow the step-by-step reconstitution guide and use the reconstitution calculator to confirm draw volumes. Review subcutaneous injection basics for technique, and always verify batch purity by reading the COA.

Frequently asked questions

What is AOD-9604 in plain language?
AOD-9604 is a research peptide we catalogue under “Healing / Recovery.” This article explains how scientists discuss it in published literature and what study types usually appear—not as a consumer product claim.

Does this page give medical advice or dosing instructions for AOD-9604?
No. Content is for laboratory and research literacy only. It does not diagnose, treat, or prevent disease, and is not a dosing guide.

Where can I see purity, variants, and pricing for AOD-9604?
Use the “View product” button to open the canonical shop listing for AOD-9604, where specifications and research SKU details are shown.

What about online case reports, before-and-after stories, or forum “logs” for AOD-9604?
Those sources are not peer-reviewed evidence. This guide focuses on preclinical literature and, where relevant, formal clinical trial programmes for drug-class molecules. Anecdotes may be interesting culturally; they are not a safe basis for dosing or medical decisions.

Need vial specs & pricing?

Open the shop listing for variants, purity notes, and research SKU details.

View product

Also known as: AOD9604, Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191, HGH Fragment Tyrosine Variant, Metabolic Pharmaceuticals AOD